Phase III randomized trial comparating concomittant administration of radiotherapy with cisplatin versus radiotherapy only for treatment of sinuses tumors and salivary glands (SANTAL)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513972-16-00

Acronym

GORTEC 2016-02

Enrollment

342

Registered

2024-08-28

Start date

2017-01-30

Completion date

Unknown

Last updated

2025-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

- Resected tumors of sinuses or salivary glands - Non-operable tumors of sinuses or salivary glands - Carcinomas of major salivary glands - Malignant tumors of sinuses

Brief summary

Progression-free survival

Detailed description

Overall survival, Quality of life, Time to locoregional progression, Time to distance progression, Rate of acute toxicity grade ≥ 3, Rate of late toxicities of grade ≥ 3, Prognostic criteria

Interventions

DRUGCisplatin 1 mg/ml Concentrate for Solution for Infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Overall survival, Quality of life, Time to locoregional progression, Time to distance progression, Rate of acute toxicity grade ≥ 3, Rate of late toxicities of grade ≥ 3, Prognostic criteria	—

Countries

Belgium, France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026